Table 1.

Univariate and mutivariates Cox regression analysis of clinical factors associated with overall survival of 247 HCC patients (LCI cohort)

Clinical variable	Univariate analysisa Hazard ratio (95% CI)	p value	Multivariates analysisb Hazard ratio (95% CI)	p value
A-HSCs specific genes (high vs. low risk)	1.95 (1.31–2.90)	0.001	1.74 (1.15–2.64)	0.008
Metastasis signature (high vs. low risk)c	1.78 (1.21–2.61)	0.003	1.53 (1.03–2.26)	0.034
Age (>50 y vs. ≤ 50 y)	1.16 (0.79–1.70)	0.437	n.a.d
Gender (male vs. female)	2.18 (1.06–4.49)	0.034	2.07 (1.00–4.31)	0.051
HBV (AVR-CC vs. CC)e	1.08 (0.69–1.68)	0.733	n.a.
HBsAg (positive vs. negative)	1.49 (0.65–3.39)	0.346	n.a.
HBeAg (positive vs. negative)	1.08 (0.69–1.68)	0.739	n.a.
Cirrhosis (yes vs. no)	2.85 (1.05–7.73)	0.040	2.11 (0.76–5.81)	0.150
ALT (numeric)	1.00 (1.00–1.00)	0.253	n.a.
Total bilirubin (numeric)	0.99 (0.96–1.02)	0.396	n.a.
Albumin (numeric)	0.96 (0.92–1.00)	0.057	n.a.
Child-Pugh score (B vs. A)	1.38 (0.79–2.43)	0.259	n.a.
AFP (numeric)	1.00 (1.00–1.00)	0.001	1.00 (1.00–1.00)	0.424
Tunor size (>3 cm vs. ≤ 3 cm)	1.85 (1.20–2.87)	0.006	n.a.
Multinodular (yes vs. no)	1.67 (1.08–2.59)	0.021	n.a.
Encapsulation (no vs. yes)	0.99 (0.64–1.51)	0.949	n.a.
Microvascular invasion (yes vs. no)	2.70 (1.47–4.97)	0.001	n.a.
BCLC staging (B + C vs. 0 + A)	3.04 (2.03–4.57)	< 0.001	2.25 (1.44–3.50)	< 0.001

Bold indicates significant p values.

Abbreviations: AVR-CC, active viral replication chronic carrier; CC, chronic carrier.

^aUnivariate analysis, Cox proportional hazards regression.

^bMutivariate analysis, Cox proportional hazards regression adjusting for gender, cirrhosis, AFP and BCLC staging.

^cThe HCC metastasis/early recurrence gene signature from Roessler et al (19).

^dn.a. not applicable

^eCC, chronic carrier, AVR-CC, active viral replication chronic carrier.